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Editorial on the Research Topic
Perspectives of Antiarrhythmic Drug Therapy: Disappointing Past, Current Efforts, and
Faint Hopes
Present issue is devoted to those areas of cardiac electrophysiology, pathophysiology, and
pharmacology which are critically important to improve the efficacy of antiarrhythmic treatment.
Cardiac arrhythmia is a leading cause of morbidity and mortality, and the history of anti-arrhythmic
drug therapies has been dismal. Development of apparently more and more selective and effective
antiarrhythmic agents has been in the focus of interest of drug research in the past few decades,
however, neither the ideal compound, nor an optimal strategy could be demonstrated so far.
Furthermore, disappointing results have been obtained with several old antiarrhythmic agents, like
many class I/C and class III drugs as documented by the CAST (Investigators of the Cardiac
Arrhythmia Suppression Trial Preliminary report, 1989) and SWORD (Waldo et al., 1995) studies,
respectively. The direct proarrhythmic side-effects of many currently applied antiarrhythmic agents
are evident by now. Some “malpractices” in the past, however, could have been prevented by
studying the actions of conventional antiarrhythmic compounds systematically in a frequency-
dependent manner. One approach may be studying the kinetics of electrical restitution of action
potential duration (APD) as presented by Árpadffy-Lovas et al. in this issue. They studied the
restitution kinetics of APD in many species, including humans, and concluded that in addition to
basic APD, some ion currents, like INa or Ito, may also modify restitution kinetics. Due to the
insufficient therapeutic results in the past we are continuously trying to find new trails, new
antiarrhythmic mechanisms (each of them, of course, will also carry its own pitfalls), such as the
suppression of late Na+ current, application of Na+/Ca2+ exchanger blockers, or selective
manipulation of CaMKII activity. All these ideas are discussed in the present issue in details.
Better understanding of the proarrhythmic mechanismsmayminimize the unwanted side-effects and
yield better therapeutic results. Accordingly, having a deeper insight into the properties of the finely tuned
myocardial Ca2+-handling, its regulatory and modulatory role in the entire cardiac electrogenesis,
including action potential morphology, pacemaker activity, and arrhythmogenesis, may allow the
development of novel antiarrhythmic strategies. The role of pathological Ca2+ handling in development
of cardiac arrhythmias is reviewed in this issue byKistamás et al. Themost important target of intracellularin.org July 2020 | Volume 11 | Article 11161
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to influence several Ca2+ sensitive ion channels. Therefore, it is not
surprising that modification of CaMKII activity is a new and
promising therapeutic strategy as presented by Nassal et al. in this
issue. In addition to activation of CaMKII, changes of intracellular
Ca2+ concentration and transmembraneCa2+ fluxes have emerging
influence on pacemaker activity through the operation of the Na+/
Ca2+ exchanger, as we learn from two articles in this issue—both
from Kohajda et al. These studies focus on interaction between the
“membrane” clock” and “calcium clock”, mechanisms which are
believed to stabilize pacemaker activity of nodal cells (Tsutsui
et al., 2018).
Since cardiac electrogenesis is basedon thewell balancedactivity
of ion channels mediating inward and outward currents,
development of sustained inward currents during the plateau,
seen frequently in the remodeled myopathic hearts, is clearly
proarrhythmic due to the increased incidence of early
afterdepolarizations. Therefore, studies on the late Na+ current,
including its CaMKII-dependent regulation, as presented by
Horváth et al. in this issue, is a new promising area of
antiarrhythmic research. Here is to be mentioned that the
antiarrhythmic efficacy of ranolazine, the well-known inhibitor of
the lateNa+ current, is partially attributable to its inhibitory potency
on TASK1 K+ channels, as reported by Ratte et al. in this issue,
concluding that “this puts forward ranolazine as a prototype drug
for the treatment of atrial arrhythmia because of its combined
efficacy on atrial electrophysiology and lower risk for ventricular
side effects”. Further approach in the treatment of persistent atrial
fibrillation may be the inhibition of other K+ currents, like the
background inward rectifier (IK1) or the acetylcholine-activated
inward rectifier (IK,ACh). Both currents are blocked by the well-
known antimalarial agent, chloroquine (which may probably be
useful against the new COVID pandemy as well). Importantly, the
efficacy against atrial fibrillation correlated with K+ current
inhibiting potencies of the drug, as reported by Tobón et al. in
this issue. In addition to electrophysiological interventions,
supporting the mechanical performance of the heart is also part
ofmodern treatment of atrialfibrillation.According to the report of
Suo et al. in this issue, the angiotensin receptor inhibitor valsartan
displayed beneficial effects in cases of atrial fibrillation and
decreased the level of heart failure.
Cardiac arrhythmias are often consequences of mutations
targeting ion channels of the surface membrane. Thus, expression
and investigation of abnormal (mutant) ion channels, as well asFrontiers in Pharmacology | www.frontiersin.org 2determination of the critical molecular segments may help to
develop more effective antiarrhythmic practices, while this track
represents new challenges as well. Since the abnormal ion channels
may be also potential drug targets, their investigation in transgenic
animal models is a promising new field of research as discussed by
Baczko et al. in this issue. In addition to in vivomodeling, in silico
modeling of ion channel gating, arrhythmia incidence, and
antiarrhythmic drug action may further improve our positions in
the antiarrhythmic offensive. Examples for this are provided by
Zhou et al. and Horgmo Jaeger et al.-both studies are presented in
this issue.
Two further reviewarticles in this issuehave tobementioned.The
one by Tosaki gives a general picture vertically from the molecular
mechanisms of cardiac arrhythmias to the new antiarrhythmic
strategies. The other by Szabó et al. does the same from the aspect
of the clinical practice in terms of emergency medicine focusing on
the problem of sudden cardiac death. Both papers give full overview
of the current stage of antiarrhythmic treatment.
Finally, when developing new antiarrhythmic strategies, based
on the suppression or activation of a cardiac ion current, it has to be
born in mind that the evolution had time enough to elaborate the
optimal duration and morphology of the cardiac action potential
(optimal, of course, under physiological conditions only) and their
modification may worsen the arrhythmia incidence. As a
consequence, we can find only better, but not ideal, new drugs
and strategies. Probably the most attractive solution in the future
should be the general introduction of personalized antiarrhythmic
treatment, whichmay improve our chances against life threatening
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